Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 2/20 | 0.30 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496666 | 0.93 | LGALS3 (0.37) | LGALS3FOLH1 | |
| SCHEMBL25900321 | 0.93 | LGALS3 (0.36) | LGALS3FOLH1P2RY2P2RY4P2RY6 | |
| SCHEMBL25496661 | 0.92 | LGALS3 (0.38) | LGALS3PKMOPRM1F2RL1SIRT2 | |
| SCHEMBL25495211 | 0.90 | LGALS3 (0.47) | LGALS3PKMOPRM1SIRT2P2RY2 | |
| SCHEMBL25982998 | 0.88 | LGALS3 (0.38) | LGALS3PKMOPRM1F2RL1SIRT2 | |
| SCHEMBL25495188 | 0.86 | LGALS3 (0.50) | LGALS3PKMOPRM1XIAPBIRC2 | |
| SCHEMBL25495212 | 0.84 | LGALS3 (0.41) | LGALS3 | |
| SCHEMBL25495210 | 0.84 | LGALS3 (0.47) | LGALS3FOLH1P2RY2P2RY4P2RY6 | |
| SCHEMBL25496669 | 0.83 | LGALS3 (0.46) | LGALS3P2RY2P2RY4P2RY6 | |
| SCHEMBL25974686 | 0.82 | LGALS3 (0.35) | LGALS3PKMOPRM1F2RL1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | LGALS3 586/4885PKM 4234/4885OPRM1 2479/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | LGALS3 243/4885PKM 3455/4885OPRM1 2084/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS3 264/4885PKM 3998/4885OPRM1 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.